The use of anticoagulant therapy plays an important role particularly in the early management of patients with acute coronary syndrome (ACS) and in those undergoing percutaneous coronary interventions (PCI). These include a variety of agents available for parenteral administration which may be chosen ...
Low-molecular-weight heparin (LMWH), derived from unfractionated heparin (UFH), has enhanced anticoagulant efficacy, long duration of action, and extended half-life. Patients receiving LMWH for preventive therapies would strongly benefit from its long-te
Heparin is widely used clinically as an anticoagulant. It is reported that heparin contains a variety of biological activities. Specially, the antitumor activity has attracted much attention. While heparin has not been used for anticancer clinically. Numerous studies have demonstrated that heparin could...
Results from large-scale trials studying the efficacy and safety of oral glycoprotein IIb/IIIa blockers in patients with ACS have been disappointing. Thrombolytic therapy is not indicated in ACS. 关键词: Acute coronary syndromes Low-molecular-weight heparin Unfractionated heparin Glycoprotein IIb/IIIa ...
along with its pharmacological activity comparable to another widely used anticoagulant, LMWH, suggest its potential efficacy as a heparin substitute. The use of bioengineered heparin with a higher anti-FXa/FIIa activity ratio can significantly improve the safety and efficacy of heparin therapy, indicati...
Initial concerns were for acute coronary syndrome (ACS); however, before anticoagulant and antithrombotic therapy was instituted, further evaluation with noncontrast computed tomography of the head showed intraventricular hemorrhage. Electrocardiographic T-wave inversions are nonspecific and have a broad ...
Anticoagulant therapy (such as LMWH) is an important treatment measure for patients with coronary heart disease combined with ACS. It is also recommended for patients with a high risk of deep vein thrombosis and pulmonary embolism. On the one hand, heparin can be an adjunct drug to PCI and ...
Acute coronary syndromes (ACS) consist of unstable angina (UA), non–ST-segment myocardial infarction (NSTEMI) and ST-segment myocardial infarction (STEMI). Timely intervention with effective, predictable antithrombin therapy is critically important in the early management of these conditions. Platelet ...
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytop... BE;Wildermann NM;et a1.The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients ...
Low-molecular weight heparin (LMWH) is increasingly used in place of unfractionated heparin in patients with acute coronary syndrome (ACS) and venous thromboembolism(VTE).Why and how monitoring LMWH has been contradictorily debated in recent years. Monitoring of therapeutic doses of UFH can be ach...